Yaping Huang

Fuzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Disproportionality analyses of acoltremon: a real-world safety assessment based on the the FDA adverse event reporting system database.

Disproportionality analyses of acoltremon: a real-world safety assessment based on the the FDA adverse event reporting system database.

Journal: Frontiers in medicine

Published: June 11, 2026

Psychiatric events induced by roflumilast: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System database.

Psychiatric events induced by roflumilast: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System database.

Journal: Frontiers in psychiatry

Published: March 23, 2026

Comprehensive pharmacovigilance analysis of lebrikizumab: a real-world safety assessment based on the FDA Adverse Event Reporting System (FAERS) database.

Comprehensive pharmacovigilance analysis of lebrikizumab: a real-world safety assessment based on the FDA Adverse Event Reporting System (FAERS) database.

Journal: Immunopharmacology and immunotoxicology

Published: March 23, 2026

Post-marketing safety monitoring of sodium-glucose cotransporter 2 inhibitors for diabetes in cats: a pharmacovigilance study based on the FDA ADAE database.

Post-marketing safety monitoring of sodium-glucose cotransporter 2 inhibitors for diabetes in cats: a pharmacovigilance study based on the FDA ADAE database.

Journal: Journal of veterinary internal medicine

Published: February 05, 2026

Disproportionality Analysis of Nemolizumab in Patients with Atopic Dermatitis: A Real-World Pharmacovigilance Study.

Disproportionality Analysis of Nemolizumab in Patients with Atopic Dermatitis: A Real-World Pharmacovigilance Study.

Journal: Dermatitis : contact, atopic, occupational, drug

Published: November 18, 2025

A real-world pharmacovigilance study of dacomitinib based on FDA adverse event reporting system (FAERS) database.

A real-world pharmacovigilance study of dacomitinib based on FDA adverse event reporting system (FAERS) database.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: October 26, 2025

Safety assessment of voclosporin: a real-world disproportionality analysis of the FAERS database.

Safety assessment of voclosporin: a real-world disproportionality analysis of the FAERS database.

Journal: Immunopharmacology and immunotoxicology

Published: October 16, 2025

Postmarketing adverse events of biologics and Janus kinase inhibitors in patients with atopic dermatitis.

Postmarketing adverse events of biologics and Janus kinase inhibitors in patients with atopic dermatitis.

Journal: Inflammopharmacology

Published: September 03, 2025

A real-world pharmacovigilance study of romidepsin based on FDA adverse event reporting system database.

A real-world pharmacovigilance study of romidepsin based on FDA adverse event reporting system database.

Journal: Frontiers in oncology

Published: August 28, 2025

Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance Study.

Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance Study.

Journal: The Journal of dermatology

Published: April 30, 2025

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database.

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database.

Journal: Frontiers in oncology

Published: April 25, 2025

Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database.

Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database.

Journal: Expert opinion on drug safety

Published: December 05, 2024

Showing 1-12 of 27

Last Updated: 09/26/2026